Company Overview and News
CENTURY Properties Group, Inc. (CPG) has pre-sold 342 vacation homes worth P2 billion in its residential tourism estate in Nasugbu, Batangas, more than nine months after it was unveiled to the market.
CPG PSKXF CPZZY PHSXY PSE
CENTURY Properties Group, Inc. (CPG) will be spending P28 billion alongside Japanese partner Mitsubishi Corp. for the rollout of 15 masterplanned communities catered toward the affordable housing market through their newly-incorporated firm.
2018-07-13 business.inquirer.net - 1
Revolution Precrafted, which designs and builds prefabricated structures for clients around the world, announced a deal to supply homes and hotel villas in Brazil.
CENTURY Properties Group, Inc. (CPG) is set to launch its second affordable housing project, where it expects to generate P2.8 billion in sales over the next three to five years.
CPG CPZZY MWP MWIDE
CENTURY Properties Group, Inc. (CPG) has partnered with Japan’s Mitsubishi Corp. for the establishment of a company that will develop affordable housing projects that are expected to generate P57 billion in sales over the next five years.
2018-05-16 business.inquirer.net - 3
Upbeat on their maiden housing project in Cavite, property developer Century Properties Group Inc. (CPG) and Mitsubishi Corp. signed on Wednesday a deal to create a new joint venture corporation that will bring to the property market around P57 billion worth of affordable homes in the next five years.
“LIVABLE COMMUNITY” isn’t exactly what comes to mind when you see the congested spaces in Metro Manila. With land becoming scarcer and real estate prices rising every year, developers would have to set up in other areas if they want to continue building livable spaces for their customers.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to PSE:CPG / Century Properties Group, Inc. on message board site Silicon Investor.
|Encore Capital Group, Inc. (ECPG)||Encore Capital Group, Inc. (ECPG)||Encore Capital Group, Inc. (ECPG)||Encore Capital Group, Inc. (ECPG)||Encore Capital Group, Inc. (ECPG)||Encore Capital Group, Inc. (ECPG)|